nodes	percent_of_prediction	percent_of_DWPC	metapath
Gemcitabine—Nucleic Acid Synthesis Inhibitors—Cytarabine—lymphatic system cancer	0.313	1	CiPCiCtD
Gemcitabine—Cytarabine—lymphatic system cancer	0.257	1	CrCtD
Gemcitabine—Lamivudine—Cytarabine—lymphatic system cancer	0.0465	0.286	CrCrCtD
Gemcitabine—Zalcitabine—Cytarabine—lymphatic system cancer	0.0402	0.248	CrCrCtD
Gemcitabine—POLD1—Cytarabine—lymphatic system cancer	0.0368	0.156	CbGbCtD
Gemcitabine—POLE—Cytarabine—lymphatic system cancer	0.0266	0.113	CbGbCtD
Gemcitabine—RRM1—Fludarabine—lymphatic system cancer	0.0259	0.11	CbGbCtD
Gemcitabine—POLA1—Fludarabine—lymphatic system cancer	0.0224	0.0949	CbGbCtD
Gemcitabine—SLC28A3—Fludarabine—lymphatic system cancer	0.0224	0.0949	CbGbCtD
Gemcitabine—CDA—Cytarabine—lymphatic system cancer	0.0211	0.0895	CbGbCtD
Gemcitabine—Cytarabine—Fludarabine—lymphatic system cancer	0.0204	0.126	CrCrCtD
Gemcitabine—Azacitidine—Fludarabine—lymphatic system cancer	0.0194	0.12	CrCrCtD
Gemcitabine—Azacitidine—Cytarabine—lymphatic system cancer	0.0183	0.113	CrCrCtD
Gemcitabine—Decitabine—Cytarabine—lymphatic system cancer	0.0175	0.108	CrCrCtD
Gemcitabine—POLA1—Cytarabine—lymphatic system cancer	0.0153	0.0647	CbGbCtD
Gemcitabine—SLC29A1—Fludarabine—lymphatic system cancer	0.0149	0.063	CbGbCtD
Gemcitabine—DCK—Fludarabine—lymphatic system cancer	0.0138	0.0584	CbGbCtD
Gemcitabine—SLC29A1—Cytarabine—lymphatic system cancer	0.0102	0.043	CbGbCtD
Gemcitabine—DCK—Cytarabine—lymphatic system cancer	0.00941	0.0399	CbGbCtD
Gemcitabine—ABCC10—Cytarabine—lymphatic system cancer	0.00776	0.0329	CbGbCtD
Gemcitabine—ABCC10—Vincristine—lymphatic system cancer	0.00368	0.0156	CbGbCtD
Gemcitabine—TYMS—Methotrexate—lymphatic system cancer	0.0027	0.0114	CbGbCtD
Gemcitabine—ABCC10—Methotrexate—lymphatic system cancer	0.00223	0.00943	CbGbCtD
Gemcitabine—ABCB1—Mitoxantrone—lymphatic system cancer	0.000498	0.00211	CbGbCtD
Gemcitabine—ABCB1—Vincristine—lymphatic system cancer	0.000343	0.00145	CbGbCtD
Gemcitabine—ABCB1—Methotrexate—lymphatic system cancer	0.000207	0.000879	CbGbCtD
Gemcitabine—RRM2—Vinorelbine—Vincristine—lymphatic system cancer	0.000112	0.132	CbGdCrCtD
Gemcitabine—POLA1—Vinblastine—Vincristine—lymphatic system cancer	0.000106	0.125	CbGdCrCtD
Gemcitabine—POLD1—Azacitidine—Fludarabine—lymphatic system cancer	9.63e-05	0.113	CbGdCrCtD
Gemcitabine—POLD1—Azacitidine—Cytarabine—lymphatic system cancer	9.1e-05	0.107	CbGdCrCtD
Gemcitabine—TYMS—Podofilox—Teniposide—lymphatic system cancer	8.07e-05	0.095	CbGdCrCtD
Gemcitabine—RRM1—Azacitidine—Fludarabine—lymphatic system cancer	7.64e-05	0.0899	CbGdCrCtD
Gemcitabine—RRM1—Azacitidine—Cytarabine—lymphatic system cancer	7.21e-05	0.0849	CbGdCrCtD
Gemcitabine—TYMS—Vinorelbine—Vincristine—lymphatic system cancer	4.8e-05	0.0565	CbGdCrCtD
Gemcitabine—RRM2—Azacitidine—Fludarabine—lymphatic system cancer	4.8e-05	0.0565	CbGdCrCtD
Gemcitabine—RRM2—Azacitidine—Cytarabine—lymphatic system cancer	4.53e-05	0.0533	CbGdCrCtD
Gemcitabine—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	4.4e-05	0.0014	CcSEcCtD
Gemcitabine—Alopecia—Bleomycin—lymphatic system cancer	4.39e-05	0.0014	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	4.39e-05	0.0014	CcSEcCtD
Gemcitabine—Stomatitis—Mitoxantrone—lymphatic system cancer	4.38e-05	0.00139	CcSEcCtD
Gemcitabine—Haemoglobin—Carmustine—lymphatic system cancer	4.36e-05	0.00139	CcSEcCtD
Gemcitabine—Haemorrhage—Carmustine—lymphatic system cancer	4.34e-05	0.00138	CcSEcCtD
Gemcitabine—Body temperature increased—Teniposide—lymphatic system cancer	4.33e-05	0.00138	CcSEcCtD
Gemcitabine—Erythema—Bleomycin—lymphatic system cancer	4.33e-05	0.00138	CcSEcCtD
Gemcitabine—Paraesthesia—Fludarabine—lymphatic system cancer	4.33e-05	0.00138	CcSEcCtD
Gemcitabine—Sweating—Mitoxantrone—lymphatic system cancer	4.31e-05	0.00137	CcSEcCtD
Gemcitabine—Dyspnoea—Fludarabine—lymphatic system cancer	4.3e-05	0.00137	CcSEcCtD
Gemcitabine—Haematuria—Mitoxantrone—lymphatic system cancer	4.29e-05	0.00136	CcSEcCtD
Gemcitabine—Oedema peripheral—Carmustine—lymphatic system cancer	4.28e-05	0.00136	CcSEcCtD
Gemcitabine—Connective tissue disorder—Carmustine—lymphatic system cancer	4.26e-05	0.00136	CcSEcCtD
Gemcitabine—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	4.23e-05	0.00135	CcSEcCtD
Gemcitabine—Ulcer—Methotrexate—lymphatic system cancer	4.23e-05	0.00135	CcSEcCtD
Gemcitabine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	4.19e-05	0.00133	CcSEcCtD
Gemcitabine—Decreased appetite—Fludarabine—lymphatic system cancer	4.19e-05	0.00133	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	4.16e-05	0.00132	CcSEcCtD
Gemcitabine—Fatigue—Fludarabine—lymphatic system cancer	4.15e-05	0.00132	CcSEcCtD
Gemcitabine—Pain—Fludarabine—lymphatic system cancer	4.12e-05	0.00131	CcSEcCtD
Gemcitabine—Constipation—Fludarabine—lymphatic system cancer	4.12e-05	0.00131	CcSEcCtD
Gemcitabine—Vasculitis—Methotrexate—lymphatic system cancer	4.1e-05	0.00131	CcSEcCtD
Gemcitabine—Urinary tract disorder—Vincristine—lymphatic system cancer	4.09e-05	0.0013	CcSEcCtD
Gemcitabine—Respiratory failure—Methotrexate—lymphatic system cancer	4.08e-05	0.0013	CcSEcCtD
Gemcitabine—Connective tissue disorder—Vincristine—lymphatic system cancer	4.07e-05	0.0013	CcSEcCtD
Gemcitabine—Urethral disorder—Vincristine—lymphatic system cancer	4.06e-05	0.00129	CcSEcCtD
Gemcitabine—Haemoglobin—Mitoxantrone—lymphatic system cancer	4.06e-05	0.00129	CcSEcCtD
Gemcitabine—Rhinitis—Mitoxantrone—lymphatic system cancer	4.04e-05	0.00129	CcSEcCtD
Gemcitabine—Haemorrhage—Mitoxantrone—lymphatic system cancer	4.03e-05	0.00128	CcSEcCtD
Gemcitabine—Ill-defined disorder—Bleomycin—lymphatic system cancer	4.02e-05	0.00128	CcSEcCtD
Gemcitabine—Pharyngitis—Mitoxantrone—lymphatic system cancer	4e-05	0.00127	CcSEcCtD
Gemcitabine—Anaemia—Bleomycin—lymphatic system cancer	4e-05	0.00127	CcSEcCtD
Gemcitabine—Feeling abnormal—Fludarabine—lymphatic system cancer	3.97e-05	0.00126	CcSEcCtD
Gemcitabine—Asthenia—Teniposide—lymphatic system cancer	3.93e-05	0.00125	CcSEcCtD
Gemcitabine—Malaise—Bleomycin—lymphatic system cancer	3.9e-05	0.00124	CcSEcCtD
Gemcitabine—Pruritus—Teniposide—lymphatic system cancer	3.88e-05	0.00123	CcSEcCtD
Gemcitabine—Arrhythmia—Carmustine—lymphatic system cancer	3.88e-05	0.00123	CcSEcCtD
Gemcitabine—Leukopenia—Bleomycin—lymphatic system cancer	3.87e-05	0.00123	CcSEcCtD
Gemcitabine—Cardiac disorder—Vincristine—lymphatic system cancer	3.84e-05	0.00122	CcSEcCtD
Gemcitabine—Alopecia—Carmustine—lymphatic system cancer	3.84e-05	0.00122	CcSEcCtD
Gemcitabine—Skin exfoliation—Methotrexate—lymphatic system cancer	3.82e-05	0.00122	CcSEcCtD
Gemcitabine—Body temperature increased—Fludarabine—lymphatic system cancer	3.81e-05	0.00121	CcSEcCtD
Gemcitabine—Erythema—Carmustine—lymphatic system cancer	3.78e-05	0.0012	CcSEcCtD
Gemcitabine—Cough—Bleomycin—lymphatic system cancer	3.78e-05	0.0012	CcSEcCtD
Gemcitabine—Angiopathy—Vincristine—lymphatic system cancer	3.76e-05	0.0012	CcSEcCtD
Gemcitabine—Diarrhoea—Teniposide—lymphatic system cancer	3.75e-05	0.00119	CcSEcCtD
Gemcitabine—Mediastinal disorder—Vincristine—lymphatic system cancer	3.73e-05	0.00119	CcSEcCtD
Gemcitabine—Chest pain—Bleomycin—lymphatic system cancer	3.68e-05	0.00117	CcSEcCtD
Gemcitabine—Myalgia—Bleomycin—lymphatic system cancer	3.68e-05	0.00117	CcSEcCtD
Gemcitabine—Alopecia—Vincristine—lymphatic system cancer	3.66e-05	0.00116	CcSEcCtD
Gemcitabine—Back pain—Carmustine—lymphatic system cancer	3.65e-05	0.00116	CcSEcCtD
Gemcitabine—Discomfort—Bleomycin—lymphatic system cancer	3.64e-05	0.00116	CcSEcCtD
Gemcitabine—Chills—Mitoxantrone—lymphatic system cancer	3.62e-05	0.00115	CcSEcCtD
Gemcitabine—Arrhythmia—Mitoxantrone—lymphatic system cancer	3.6e-05	0.00115	CcSEcCtD
Gemcitabine—Alopecia—Mitoxantrone—lymphatic system cancer	3.57e-05	0.00113	CcSEcCtD
Gemcitabine—Pulmonary oedema—Methotrexate—lymphatic system cancer	3.56e-05	0.00113	CcSEcCtD
Gemcitabine—Anaphylactic shock—Bleomycin—lymphatic system cancer	3.53e-05	0.00112	CcSEcCtD
Gemcitabine—Oedema—Bleomycin—lymphatic system cancer	3.53e-05	0.00112	CcSEcCtD
Gemcitabine—Erythema—Mitoxantrone—lymphatic system cancer	3.51e-05	0.00112	CcSEcCtD
Gemcitabine—Infection—Bleomycin—lymphatic system cancer	3.51e-05	0.00112	CcSEcCtD
Gemcitabine—Anaemia—Carmustine—lymphatic system cancer	3.49e-05	0.00111	CcSEcCtD
Gemcitabine—Back pain—Vincristine—lymphatic system cancer	3.49e-05	0.00111	CcSEcCtD
Gemcitabine—Vomiting—Teniposide—lymphatic system cancer	3.49e-05	0.00111	CcSEcCtD
Gemcitabine—Sepsis—Methotrexate—lymphatic system cancer	3.47e-05	0.00111	CcSEcCtD
Gemcitabine—Thrombocytopenia—Bleomycin—lymphatic system cancer	3.46e-05	0.0011	CcSEcCtD
Gemcitabine—Asthenia—Fludarabine—lymphatic system cancer	3.46e-05	0.0011	CcSEcCtD
Gemcitabine—Rash—Teniposide—lymphatic system cancer	3.46e-05	0.0011	CcSEcCtD
Gemcitabine—Dermatitis—Teniposide—lymphatic system cancer	3.45e-05	0.0011	CcSEcCtD
Gemcitabine—Headache—Teniposide—lymphatic system cancer	3.43e-05	0.00109	CcSEcCtD
Gemcitabine—Pruritus—Fludarabine—lymphatic system cancer	3.41e-05	0.00108	CcSEcCtD
Gemcitabine—Back pain—Mitoxantrone—lymphatic system cancer	3.4e-05	0.00108	CcSEcCtD
Gemcitabine—Leukopenia—Carmustine—lymphatic system cancer	3.38e-05	0.00108	CcSEcCtD
Gemcitabine—Anorexia—Bleomycin—lymphatic system cancer	3.37e-05	0.00107	CcSEcCtD
Gemcitabine—Anaemia—Vincristine—lymphatic system cancer	3.33e-05	0.00106	CcSEcCtD
Gemcitabine—TYMS—Vinblastine—Vincristine—lymphatic system cancer	3.3e-05	0.0389	CbGdCrCtD
Gemcitabine—Hypotension—Bleomycin—lymphatic system cancer	3.3e-05	0.00105	CcSEcCtD
Gemcitabine—Diarrhoea—Fludarabine—lymphatic system cancer	3.3e-05	0.00105	CcSEcCtD
Gemcitabine—Hypertension—Carmustine—lymphatic system cancer	3.26e-05	0.00104	CcSEcCtD
Gemcitabine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	3.26e-05	0.00104	CcSEcCtD
Gemcitabine—Nausea—Teniposide—lymphatic system cancer	3.26e-05	0.00104	CcSEcCtD
Gemcitabine—Anaemia—Mitoxantrone—lymphatic system cancer	3.25e-05	0.00103	CcSEcCtD
Gemcitabine—Hepatic failure—Methotrexate—lymphatic system cancer	3.23e-05	0.00103	CcSEcCtD
Gemcitabine—Leukopenia—Vincristine—lymphatic system cancer	3.23e-05	0.00103	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	3.22e-05	0.00102	CcSEcCtD
Gemcitabine—Chest pain—Carmustine—lymphatic system cancer	3.22e-05	0.00102	CcSEcCtD
Gemcitabine—Myalgia—Carmustine—lymphatic system cancer	3.22e-05	0.00102	CcSEcCtD
Gemcitabine—Paraesthesia—Bleomycin—lymphatic system cancer	3.17e-05	0.00101	CcSEcCtD
Gemcitabine—Malaise—Mitoxantrone—lymphatic system cancer	3.17e-05	0.00101	CcSEcCtD
Gemcitabine—Dyspnoea—Bleomycin—lymphatic system cancer	3.15e-05	0.001	CcSEcCtD
Gemcitabine—Leukopenia—Mitoxantrone—lymphatic system cancer	3.14e-05	0.001	CcSEcCtD
Gemcitabine—Hypertension—Vincristine—lymphatic system cancer	3.11e-05	0.000991	CcSEcCtD
Gemcitabine—Oedema—Carmustine—lymphatic system cancer	3.08e-05	0.000981	CcSEcCtD
Gemcitabine—Decreased appetite—Bleomycin—lymphatic system cancer	3.07e-05	0.000977	CcSEcCtD
Gemcitabine—Myalgia—Vincristine—lymphatic system cancer	3.07e-05	0.000977	CcSEcCtD
Gemcitabine—Cough—Mitoxantrone—lymphatic system cancer	3.06e-05	0.000975	CcSEcCtD
Gemcitabine—Infection—Carmustine—lymphatic system cancer	3.06e-05	0.000975	CcSEcCtD
Gemcitabine—Vomiting—Fludarabine—lymphatic system cancer	3.06e-05	0.000975	CcSEcCtD
Gemcitabine—Rash—Fludarabine—lymphatic system cancer	3.04e-05	0.000967	CcSEcCtD
Gemcitabine—Dermatitis—Fludarabine—lymphatic system cancer	3.03e-05	0.000966	CcSEcCtD
Gemcitabine—Hypertension—Mitoxantrone—lymphatic system cancer	3.03e-05	0.000965	CcSEcCtD
Gemcitabine—Pain—Bleomycin—lymphatic system cancer	3.02e-05	0.000961	CcSEcCtD
Gemcitabine—Thrombocytopenia—Carmustine—lymphatic system cancer	3.02e-05	0.000961	CcSEcCtD
Gemcitabine—Headache—Fludarabine—lymphatic system cancer	3.02e-05	0.00096	CcSEcCtD
Gemcitabine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	3e-05	0.000955	CcSEcCtD
Gemcitabine—Chest pain—Mitoxantrone—lymphatic system cancer	2.99e-05	0.000951	CcSEcCtD
Gemcitabine—Arthralgia—Mitoxantrone—lymphatic system cancer	2.99e-05	0.000951	CcSEcCtD
Gemcitabine—Myalgia—Mitoxantrone—lymphatic system cancer	2.99e-05	0.000951	CcSEcCtD
Gemcitabine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	2.97e-05	0.000944	CcSEcCtD
Gemcitabine—Discomfort—Mitoxantrone—lymphatic system cancer	2.95e-05	0.00094	CcSEcCtD
Gemcitabine—Oedema—Vincristine—lymphatic system cancer	2.94e-05	0.000937	CcSEcCtD
Gemcitabine—Anaphylactic shock—Vincristine—lymphatic system cancer	2.94e-05	0.000937	CcSEcCtD
Gemcitabine—Anorexia—Carmustine—lymphatic system cancer	2.94e-05	0.000935	CcSEcCtD
Gemcitabine—Infection—Vincristine—lymphatic system cancer	2.92e-05	0.00093	CcSEcCtD
Gemcitabine—Feeling abnormal—Bleomycin—lymphatic system cancer	2.91e-05	0.000926	CcSEcCtD
Gemcitabine—Nervous system disorder—Vincristine—lymphatic system cancer	2.89e-05	0.000918	CcSEcCtD
Gemcitabine—Thrombocytopenia—Vincristine—lymphatic system cancer	2.88e-05	0.000917	CcSEcCtD
Gemcitabine—Hypotension—Carmustine—lymphatic system cancer	2.88e-05	0.000917	CcSEcCtD
Gemcitabine—Oedema—Mitoxantrone—lymphatic system cancer	2.87e-05	0.000912	CcSEcCtD
Gemcitabine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	2.87e-05	0.000912	CcSEcCtD
Gemcitabine—Nausea—Fludarabine—lymphatic system cancer	2.86e-05	0.000911	CcSEcCtD
Gemcitabine—Infection—Mitoxantrone—lymphatic system cancer	2.85e-05	0.000906	CcSEcCtD
Gemcitabine—Hyperhidrosis—Vincristine—lymphatic system cancer	2.85e-05	0.000905	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	2.81e-05	0.000894	CcSEcCtD
Gemcitabine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	2.81e-05	0.000893	CcSEcCtD
Gemcitabine—Anorexia—Vincristine—lymphatic system cancer	2.81e-05	0.000893	CcSEcCtD
Gemcitabine—Body temperature increased—Bleomycin—lymphatic system cancer	2.79e-05	0.000889	CcSEcCtD
Gemcitabine—Insomnia—Carmustine—lymphatic system cancer	2.79e-05	0.000887	CcSEcCtD
Gemcitabine—Skin disorder—Mitoxantrone—lymphatic system cancer	2.78e-05	0.000886	CcSEcCtD
Gemcitabine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	2.77e-05	0.000882	CcSEcCtD
Gemcitabine—Paraesthesia—Carmustine—lymphatic system cancer	2.77e-05	0.000881	CcSEcCtD
Gemcitabine—Hypotension—Vincristine—lymphatic system cancer	2.75e-05	0.000875	CcSEcCtD
Gemcitabine—Dyspnoea—Carmustine—lymphatic system cancer	2.75e-05	0.000875	CcSEcCtD
Gemcitabine—Somnolence—Carmustine—lymphatic system cancer	2.74e-05	0.000872	CcSEcCtD
Gemcitabine—Anorexia—Mitoxantrone—lymphatic system cancer	2.73e-05	0.000869	CcSEcCtD
Gemcitabine—Liver function test abnormal—Methotrexate—lymphatic system cancer	2.68e-05	0.000854	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	2.68e-05	0.000853	CcSEcCtD
Gemcitabine—Decreased appetite—Carmustine—lymphatic system cancer	2.68e-05	0.000853	CcSEcCtD
Gemcitabine—Hypotension—Mitoxantrone—lymphatic system cancer	2.68e-05	0.000852	CcSEcCtD
Gemcitabine—Insomnia—Vincristine—lymphatic system cancer	2.66e-05	0.000847	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	2.66e-05	0.000847	CcSEcCtD
Gemcitabine—Paraesthesia—Vincristine—lymphatic system cancer	2.64e-05	0.000841	CcSEcCtD
Gemcitabine—Constipation—Carmustine—lymphatic system cancer	2.64e-05	0.000839	CcSEcCtD
Gemcitabine—Pain—Carmustine—lymphatic system cancer	2.64e-05	0.000839	CcSEcCtD
Gemcitabine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	2.62e-05	0.000833	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	2.61e-05	0.000831	CcSEcCtD
Gemcitabine—Paraesthesia—Mitoxantrone—lymphatic system cancer	2.57e-05	0.000819	CcSEcCtD
Gemcitabine—Decreased appetite—Vincristine—lymphatic system cancer	2.56e-05	0.000814	CcSEcCtD
Gemcitabine—Dyspnoea—Mitoxantrone—lymphatic system cancer	2.56e-05	0.000813	CcSEcCtD
Gemcitabine—Somnolence—Mitoxantrone—lymphatic system cancer	2.55e-05	0.000811	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	2.54e-05	0.000809	CcSEcCtD
Gemcitabine—Feeling abnormal—Carmustine—lymphatic system cancer	2.54e-05	0.000808	CcSEcCtD
Gemcitabine—Fatigue—Vincristine—lymphatic system cancer	2.54e-05	0.000807	CcSEcCtD
Gemcitabine—Asthenia—Bleomycin—lymphatic system cancer	2.53e-05	0.000806	CcSEcCtD
Gemcitabine—Pain—Vincristine—lymphatic system cancer	2.52e-05	0.000801	CcSEcCtD
Gemcitabine—Constipation—Vincristine—lymphatic system cancer	2.52e-05	0.000801	CcSEcCtD
Gemcitabine—Pruritus—Bleomycin—lymphatic system cancer	2.5e-05	0.000795	CcSEcCtD
Gemcitabine—Decreased appetite—Mitoxantrone—lymphatic system cancer	2.49e-05	0.000793	CcSEcCtD
Gemcitabine—Fatigue—Mitoxantrone—lymphatic system cancer	2.47e-05	0.000786	CcSEcCtD
Gemcitabine—Pain—Mitoxantrone—lymphatic system cancer	2.45e-05	0.00078	CcSEcCtD
Gemcitabine—Constipation—Mitoxantrone—lymphatic system cancer	2.45e-05	0.00078	CcSEcCtD
Gemcitabine—Body temperature increased—Carmustine—lymphatic system cancer	2.44e-05	0.000776	CcSEcCtD
Gemcitabine—Pancytopenia—Methotrexate—lymphatic system cancer	2.39e-05	0.000759	CcSEcCtD
Gemcitabine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	2.36e-05	0.000752	CcSEcCtD
Gemcitabine—Neutropenia—Methotrexate—lymphatic system cancer	2.35e-05	0.000747	CcSEcCtD
Gemcitabine—Body temperature increased—Vincristine—lymphatic system cancer	2.33e-05	0.00074	CcSEcCtD
Gemcitabine—Body temperature increased—Mitoxantrone—lymphatic system cancer	2.27e-05	0.000721	CcSEcCtD
Gemcitabine—Pneumonia—Methotrexate—lymphatic system cancer	2.25e-05	0.000717	CcSEcCtD
Gemcitabine—Vomiting—Bleomycin—lymphatic system cancer	2.25e-05	0.000715	CcSEcCtD
Gemcitabine—Rash—Bleomycin—lymphatic system cancer	2.23e-05	0.000709	CcSEcCtD
Gemcitabine—Dermatitis—Bleomycin—lymphatic system cancer	2.23e-05	0.000708	CcSEcCtD
Gemcitabine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	2.22e-05	0.000706	CcSEcCtD
Gemcitabine—Asthenia—Carmustine—lymphatic system cancer	2.21e-05	0.000704	CcSEcCtD
Gemcitabine—Renal failure—Methotrexate—lymphatic system cancer	2.2e-05	0.0007	CcSEcCtD
Gemcitabine—Stomatitis—Methotrexate—lymphatic system cancer	2.18e-05	0.000695	CcSEcCtD
Gemcitabine—Sweating—Methotrexate—lymphatic system cancer	2.15e-05	0.000683	CcSEcCtD
Gemcitabine—Haematuria—Methotrexate—lymphatic system cancer	2.14e-05	0.000679	CcSEcCtD
Gemcitabine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	2.12e-05	0.000674	CcSEcCtD
Gemcitabine—Asthenia—Vincristine—lymphatic system cancer	2.11e-05	0.000672	CcSEcCtD
Gemcitabine—Diarrhoea—Carmustine—lymphatic system cancer	2.11e-05	0.000671	CcSEcCtD
Gemcitabine—Nausea—Bleomycin—lymphatic system cancer	2.1e-05	0.000668	CcSEcCtD
Gemcitabine—Agranulocytosis—Methotrexate—lymphatic system cancer	2.09e-05	0.000665	CcSEcCtD
Gemcitabine—Asthenia—Mitoxantrone—lymphatic system cancer	2.06e-05	0.000654	CcSEcCtD
Gemcitabine—TYMS—Azacitidine—Fludarabine—lymphatic system cancer	2.05e-05	0.0241	CbGdCrCtD
Gemcitabine—Haemoglobin—Methotrexate—lymphatic system cancer	2.02e-05	0.000643	CcSEcCtD
Gemcitabine—Diarrhoea—Vincristine—lymphatic system cancer	2.01e-05	0.000641	CcSEcCtD
Gemcitabine—Haemorrhage—Methotrexate—lymphatic system cancer	2.01e-05	0.00064	CcSEcCtD
Gemcitabine—Pharyngitis—Methotrexate—lymphatic system cancer	2e-05	0.000635	CcSEcCtD
Gemcitabine—Urinary tract disorder—Methotrexate—lymphatic system cancer	1.99e-05	0.000632	CcSEcCtD
Gemcitabine—Urethral disorder—Methotrexate—lymphatic system cancer	1.97e-05	0.000627	CcSEcCtD
Gemcitabine—Diarrhoea—Mitoxantrone—lymphatic system cancer	1.96e-05	0.000624	CcSEcCtD
Gemcitabine—Vomiting—Carmustine—lymphatic system cancer	1.96e-05	0.000624	CcSEcCtD
Gemcitabine—Rash—Carmustine—lymphatic system cancer	1.94e-05	0.000619	CcSEcCtD
Gemcitabine—Dermatitis—Carmustine—lymphatic system cancer	1.94e-05	0.000618	CcSEcCtD
Gemcitabine—TYMS—Azacitidine—Cytarabine—lymphatic system cancer	1.94e-05	0.0228	CbGdCrCtD
Gemcitabine—Headache—Carmustine—lymphatic system cancer	1.93e-05	0.000615	CcSEcCtD
Gemcitabine—Erythema multiforme—Methotrexate—lymphatic system cancer	1.9e-05	0.000605	CcSEcCtD
Gemcitabine—Vomiting—Vincristine—lymphatic system cancer	1.87e-05	0.000595	CcSEcCtD
Gemcitabine—Cardiac disorder—Methotrexate—lymphatic system cancer	1.87e-05	0.000594	CcSEcCtD
Gemcitabine—Rash—Vincristine—lymphatic system cancer	1.86e-05	0.000591	CcSEcCtD
Gemcitabine—Dermatitis—Vincristine—lymphatic system cancer	1.85e-05	0.00059	CcSEcCtD
Gemcitabine—Headache—Vincristine—lymphatic system cancer	1.84e-05	0.000587	CcSEcCtD
Gemcitabine—Nausea—Carmustine—lymphatic system cancer	1.83e-05	0.000583	CcSEcCtD
Gemcitabine—Angiopathy—Methotrexate—lymphatic system cancer	1.82e-05	0.00058	CcSEcCtD
Gemcitabine—Vomiting—Mitoxantrone—lymphatic system cancer	1.82e-05	0.00058	CcSEcCtD
Gemcitabine—Immune system disorder—Methotrexate—lymphatic system cancer	1.82e-05	0.000578	CcSEcCtD
Gemcitabine—Mediastinal disorder—Methotrexate—lymphatic system cancer	1.81e-05	0.000576	CcSEcCtD
Gemcitabine—Rash—Mitoxantrone—lymphatic system cancer	1.81e-05	0.000575	CcSEcCtD
Gemcitabine—Dermatitis—Mitoxantrone—lymphatic system cancer	1.81e-05	0.000575	CcSEcCtD
Gemcitabine—Chills—Methotrexate—lymphatic system cancer	1.8e-05	0.000574	CcSEcCtD
Gemcitabine—Headache—Mitoxantrone—lymphatic system cancer	1.8e-05	0.000571	CcSEcCtD
Gemcitabine—Alopecia—Methotrexate—lymphatic system cancer	1.78e-05	0.000565	CcSEcCtD
Gemcitabine—Erythema—Methotrexate—lymphatic system cancer	1.75e-05	0.000557	CcSEcCtD
Gemcitabine—Nausea—Vincristine—lymphatic system cancer	1.75e-05	0.000556	CcSEcCtD
Gemcitabine—Nausea—Mitoxantrone—lymphatic system cancer	1.7e-05	0.000542	CcSEcCtD
Gemcitabine—Back pain—Methotrexate—lymphatic system cancer	1.69e-05	0.000539	CcSEcCtD
Gemcitabine—Ill-defined disorder—Methotrexate—lymphatic system cancer	1.62e-05	0.000517	CcSEcCtD
Gemcitabine—Anaemia—Methotrexate—lymphatic system cancer	1.62e-05	0.000515	CcSEcCtD
Gemcitabine—Malaise—Methotrexate—lymphatic system cancer	1.58e-05	0.000502	CcSEcCtD
Gemcitabine—Leukopenia—Methotrexate—lymphatic system cancer	1.57e-05	0.000498	CcSEcCtD
Gemcitabine—Cough—Methotrexate—lymphatic system cancer	1.53e-05	0.000486	CcSEcCtD
Gemcitabine—Arthralgia—Methotrexate—lymphatic system cancer	1.49e-05	0.000474	CcSEcCtD
Gemcitabine—Myalgia—Methotrexate—lymphatic system cancer	1.49e-05	0.000474	CcSEcCtD
Gemcitabine—Chest pain—Methotrexate—lymphatic system cancer	1.49e-05	0.000474	CcSEcCtD
Gemcitabine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	1.48e-05	0.000471	CcSEcCtD
Gemcitabine—Discomfort—Methotrexate—lymphatic system cancer	1.47e-05	0.000468	CcSEcCtD
Gemcitabine—Anaphylactic shock—Methotrexate—lymphatic system cancer	1.43e-05	0.000454	CcSEcCtD
Gemcitabine—Infection—Methotrexate—lymphatic system cancer	1.42e-05	0.000451	CcSEcCtD
Gemcitabine—Nervous system disorder—Methotrexate—lymphatic system cancer	1.4e-05	0.000446	CcSEcCtD
Gemcitabine—Thrombocytopenia—Methotrexate—lymphatic system cancer	1.4e-05	0.000445	CcSEcCtD
Gemcitabine—Skin disorder—Methotrexate—lymphatic system cancer	1.39e-05	0.000441	CcSEcCtD
Gemcitabine—Hyperhidrosis—Methotrexate—lymphatic system cancer	1.38e-05	0.000439	CcSEcCtD
Gemcitabine—Anorexia—Methotrexate—lymphatic system cancer	1.36e-05	0.000433	CcSEcCtD
Gemcitabine—Hypotension—Methotrexate—lymphatic system cancer	1.33e-05	0.000425	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	1.3e-05	0.000414	CcSEcCtD
Gemcitabine—Insomnia—Methotrexate—lymphatic system cancer	1.29e-05	0.000411	CcSEcCtD
Gemcitabine—Paraesthesia—Methotrexate—lymphatic system cancer	1.28e-05	0.000408	CcSEcCtD
Gemcitabine—Dyspnoea—Methotrexate—lymphatic system cancer	1.27e-05	0.000405	CcSEcCtD
Gemcitabine—Somnolence—Methotrexate—lymphatic system cancer	1.27e-05	0.000404	CcSEcCtD
Gemcitabine—Decreased appetite—Methotrexate—lymphatic system cancer	1.24e-05	0.000395	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	1.23e-05	0.000392	CcSEcCtD
Gemcitabine—Fatigue—Methotrexate—lymphatic system cancer	1.23e-05	0.000392	CcSEcCtD
Gemcitabine—Pain—Methotrexate—lymphatic system cancer	1.22e-05	0.000389	CcSEcCtD
Gemcitabine—Feeling abnormal—Methotrexate—lymphatic system cancer	1.18e-05	0.000374	CcSEcCtD
Gemcitabine—Body temperature increased—Methotrexate—lymphatic system cancer	1.13e-05	0.000359	CcSEcCtD
Gemcitabine—Asthenia—Methotrexate—lymphatic system cancer	1.02e-05	0.000326	CcSEcCtD
Gemcitabine—Pruritus—Methotrexate—lymphatic system cancer	1.01e-05	0.000322	CcSEcCtD
Gemcitabine—Diarrhoea—Methotrexate—lymphatic system cancer	9.77e-06	0.000311	CcSEcCtD
Gemcitabine—Vomiting—Methotrexate—lymphatic system cancer	9.08e-06	0.000289	CcSEcCtD
Gemcitabine—Rash—Methotrexate—lymphatic system cancer	9e-06	0.000287	CcSEcCtD
Gemcitabine—Dermatitis—Methotrexate—lymphatic system cancer	9e-06	0.000286	CcSEcCtD
Gemcitabine—Headache—Methotrexate—lymphatic system cancer	8.95e-06	0.000285	CcSEcCtD
Gemcitabine—Nausea—Methotrexate—lymphatic system cancer	8.48e-06	0.00027	CcSEcCtD
